Last Updated : August 27, 2024
Details
FilesGeneric Name:
Nivolumab and Ipilimumab
Project Status:
Complete
Therapeutic Area:
Melanoma (Skin)
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Sub Line:
Oncology Single Drug Reviews (Non-Sponsored)
Project Number:
PX0347-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Fee Schedule:
Pending
Indications:
In combination, for the first-line treatment of adult patients with advanced (unresectable or metastatic) melanoma when patients progress during or within 6 months of adjuvant PD-1 therapy.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Call for patient/clinician input open | 09-Nov-23 |
---|---|
Call for patient/clinician input closed | 08-Jan-24 |
Call for industry input open | 09-Nov-23 |
Call for industry input closed | 08-Jan-24 |
Submission received | 24-Oct-23 |
Files
Last Updated : August 27, 2024